Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | ARG1 | P05089 | 5/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3463284 | 1.00 | SLC1A2 (1.00) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL2177035 | 1.00 | SLC1A2 (1.00) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL2177045 | 1.00 | SLC1A2 (1.00) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL21402233 | 0.98 | SLC1A2 (0.95) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL17743458 | 0.98 | SLC1A2 (0.95) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL28347967 | 0.89 | MEN1 (0.96) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL730491 | 0.86 | MEN1 (1.00) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL6342925 | 0.86 | MEN1 (1.00) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL730489 | 0.86 | MEN1 (1.00) | SLC1A2MEN1BLMKMT2ASLC1A1 | |
| SCHEMBL6342928 | 0.86 | MEN1 (1.00) | SLC1A2MEN1BLMKMT2ASLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| CN-102548640-B | Carbon dioxide absorbing liquid | TOSHIBA KK | 2015-02-18 | — | — | CN | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| EP-2170260-A1 | AZO DERIVATIVES CONTAINING A PYRAZOLINONE UNIT FOR DYEING KERATIN FIBRES | L'Oreal (FR) | 2010-04-07 | — | — | EP | claimed |
| WO-2009000753-A1 | AZO DERIVATIVES CONTAINING A PYRAZOLINONE UNIT FOR DYEING KERATIN FIBRES | L'OREAL (FR) | 2008-12-31 | — | — | WO | claimed |
| US-20070007489-A1 | Heat transfer medium composition | SHISHIAI-KABUSHIKIGAISHA (JP) | 2007-01-11 | — | — | US | claimed |
| EP-1698678-A1 | HEAT CARRIER COMPOSITION | Shishiai-Kabushikigaisha (JP) | 2006-09-06 | — | — | EP | claimed |
| EP-4204100-A1 | HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE | L'OREAL (FR) | 2023-07-05 | — | — | EP | disclosed |
| CN-116322616-A | Hair lightening compositions providing damage protection and sensory benefits and methods of use | 欧莱雅 | 2023-06-23 | — | — | CN | disclosed |
| US-11559474-B2 | Hair lightening compositions and methods of use | L'OREAL (FR) | 2023-01-24 | — | — | US | disclosed |
| WO-2022047081-A1 | HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE | HENRY DEREK (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-106794264-B | Conjugates comprising neurotensin receptor ligands and uses thereof | 3B制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-10799605-B2 | Conjugate comprising a neurotensin receptor ligand and use thereof | 3B PHARMACEUTICALS GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | L'OREAL (FR) | 2009-01-29 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070007489-A1 | Heat transfer medium composition | SHISHIAI-KABUSHIKIGAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1698678-A1 | HEAT CARRIER COMPOSITION | Shishiai-Kabushikigaisha (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | SLC1A2 4244/4885MEN1 2029/4885BLM 3099/4885 |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | CUTA, SYMPK, TPRKB | SLC1A2 4811/4885MEN1 452/4885BLM 350/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | SLC1A2 3491/4885MEN1 748/4885BLM 1845/4885 |
| US-10799605-B2 | Conjugate comprising a neurotensin receptor ligand and use thereof | NTSR1, NTSR2, TAAR1 | SLC1A2 89/4885MEN1 551/4885BLM 4827/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | SLC1A2 2201/4885MEN1 3782/4885BLM 3026/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | SLC1A2 2042/4885MEN1 3168/4885BLM 2877/4885 |
| US-11559474-B2 | Hair lightening compositions and methods of use | TYR, ALAD, CYBA | SLC1A2 333/4885MEN1 2921/4885BLM 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.